-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Regulatory Perspective: Why RWD is Critical for Evaluation of SCD Disease Modifying Curative Therapies

Program: Special-Interest Sessions
Session: ASH Research Collaborative Data Hub Sickle Cell Disease Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation
Monday, December 9, 2024, 4:30 PM-6:00 PM

Nicole Verdun, MD

FDA, Silver Spring, MD

Disclosures: No relevant conflicts of interest to declare.

See more of: ASH Research Collaborative Data Hub Sickle Cell Disease Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>